Clinical trial
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Ustekinumab Therapy in Subjects With Moderately to Severely Active Crohn's Disease Previously Treated With TNF Antagonist Therapy
NCT00771667 is registered in ClinicalTrials.gov with Centocor, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Ustekinumab Therapy in Subjects With Moderately to Severely Active Crohn's Disease Previously Treated With TNF Antagonist Therapy
- Lead sponsor
- Centocor, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 31, 2008
- Completion date
- December 31, 2010
- Enrollment
- 526 (actual)
- Sites
- 174
Conditions
As the registry lists them; a condition with its own page is linked.
crohn's disease